News

Latest news: Quotient Sciences Completes Integration of Drug Substance Into Translational Pharmaceutics Platform

Access Press Release

Search

32 results for "Translational Pharmaceutics"

Tufts CSDD Study Assessing the Financial Benefits of Translational Pharmaceutics®: A Platform for Accelerating Product Development

This webinar summarizes the key findings of the recent Tufts CSDD research into Translational Pharmaceutics, the innovative approach to drug development. Access our on-demand webinar now.

Translational Pharmaceutics

Assessing the Financial Impact of Translational Pharmaceutics®

Application of Translational Pharmaceutics® to reduce time, cost and risk in the early development of inhaled drug products - RDD

The efficiency and effectiveness of new drug development has remained problematic over the last decade. Translational Pharmaceutics has emerged as a new paradigm to improve R&D productivity.

Application of Translational Pharmaceutics in Accelerating the Development of MR Dosage Forms

Poster presentation at NERDG 2021 Annual Meeting. In this poster we demonstrate an optimized approach to developing oral modified-release (MR) dosage forms using the Translational Pharmaceutics platform. This approach uses emerging human data to inform adjustment of formulation composition in an adaptive clinical study.

Dramatically Reduce Your Development Time and Costs with Translational Pharmaceutics®

Assessing the Financial Impact of Translational Pharmaceutics®

Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.

Reduce Your Drug Development Time and Costs with Translational Pharmaceutics®

Translational Pharmaceutics

Quotient Sciences helps you achieve your goals by enabling precise formulation development, streamlined manufacturing, quick pivot to clinical data and a significantly faster transition through drug development.

Assessing the financial impact of Translational Pharmaceutics®

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is taking advantage of Quotient Sciences’ Translational Pharmaceutics® platform and First-In-Human program for the development of BCX4161, a promising candidate for the treatment of hereditary angioedema.

A rapid formulation development and clinical testing program to evaluate the pharmacokinetics of a novel enabled formulation of abiraterone acetate - AAPS 2016

Following initial dosing, the Translational Pharmaceutics platform also allows GMP drug products to be made in real-time in response to interim analysis of clinical data, typically on a 7-14 day cycle.

Xspray

Protein kinase inhibitors (PKIs) are used in the treatment of cancer and inflammation, but food interactions are a common problem with this class of drugs. Swedish drug delivery company Xspray has used its Hybrid Nanoparticle (HyNap™) technology to improve the bioavailability of the PKI nilotinib, reducing the required dose and significantly lowering the food interaction of the drug compared with the marketed product.

Accelerating drug product development from early phase to scale up and commercialisation

This webinar covers a real-world case study with Druggability Technologies, a specialty pharmaceutical company, which utilized Quotient’s integrated approach to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib, using proprietary super-API compositions developed by DRGT.

Inhaled Drug Development Webinar- Dec. 9

Register today for our inhalation focused webinar series taking place on Thursday December 9th entitled: Formulation Development Challenges & Pitfalls When Developing Dry Powder Inhalers (DPIs)

Inhaled Drug Development Webinar- Dec. 14

Register today for our inhalation focused webinar series taking place on Tuesday, December 14th entitled: Formulation Development Challenges & Pitfalls When Developing Dry Powder Inhalers (DPIs)

Inhaled Drug Development Webinar Series

Register today for our inhalation focused webinar series taking place on December 7th,9th, & 14th entitled: Formulation Development Challenges & Pitfalls When Developing Dry Powder Inhalers (DPIs)

AAPS Northeast Regional Discussion Group (AAPS- NERDG)- April 2021

Connect with Quotient at the upcoming virtual AAPS Northeast Regional Discussion Group (AAPS- NERDG) Event

Inhaled Drug Development Webinar- Dec. 7

Register today for our inhalation focused webinar series taking place on Tuesday, December 7th entitled: Formulation Development Challenges & Pitfalls When Developing Dry Powder Inhalers (DPIs)

How to Reduce the Time and Cost for Optimizing Drug Product Formulations

Join industry experts John McDermott, Executive Director of Drug Product Optimization, and Kieran Crowley, Senior Scientific Director, both from Quotient Scienbces, as they outline studies and metrics in drug delivery and drug product optimization.

Pediatrics

MEI Pharma

MEI Pharma has leveraged Quotient's Translational Pharmaceutics® platform to expedite development of its next-generation cancer therapy ME-401.

Enhanced formulation decision-making in early phase clinical trials for parenteral products

This presentation describes the principles and applications of Translational Pharmaceutics: an R&D platform integrating formulation development, real-time adaptive GMP manufacturing and clinical testing in order to accelerate drug development cycles.

First-in-Human to Proof-of-Concept

Our Translational Pharmaceutics approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.

AAPS 2019 Poster- A Phase I Study Allowing Clinical Screening of Multiple Solubility-Enhancement Formulation Technologies, and an Assessment of Food, PPI and Dose Linearity Assessment with the Selected Formulation of BOS172767, in Healthy Volunteers

Presented at AAPS 2019: Translational Pharmaceutics was used to evaluate three BOS172767 formulations in on a integrated clinical study, and successfully identified the micronized capsule as the new lead formulation. This formulation had superior exposure compared to the IR reference capsules, and approximate proportional increase in exposure up to 800 mg. The food effect observed at 100 mg was reduced compared to that previously seen at 200 mg (FIH capsule) and elevated gastric pH (subjects taking PPIs) had minimal effect on exposure. A Level C IVIVC was achieved with a biorelevant dissolution test, which provides valuable information for future formulation development and setting of product specifications.

Getting it Right Early- The Importance of Biopharmaceutics in Early Drug Development - Boston

Join us for a complimentary lunch seminar to learn effective strategies that biotech and pharmaceutical companies are using to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline and explore alternative approaches for accelerating your early development plan.

Getting it Right Early- The Importance of Biopharmaceutics in Early Drug Development - Webinar

Join us for a webinar to learn effective strategies that biotech and pharmaceutical companies are using to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline and explore alternative approaches for accelerating your early development plan.

Accelerating Development Through Integrated Drug Substance & Drug Product Strategies | RTP Seminar

Join our complimentary lunch seminar in Research Triangle Park, North Carolina, on June 9th and learn how a fully integrated program can speed up transition from candidate selection to proof of concept and shorten the pathway to clinical development.

Boston Lunch Seminar: Integrated Drug Substance & Drug Product Strategies- May 11

Save your spot for our upcoming lunch seminar in Cambridge, MA on May 11 entitled: "Accelerating Development Through Integrated Drug Substance & Drug Product Strategies: Fully integrated programs to shorten the clinical pathway"

Accelerating Development Through Integrated Drug Substance & Drug Product Strategies | April 28th Webinar

Register today for our live webinar on April 28 to learn how a fully integrated program can speed up transition from candidate selection to proof of concept and shorten the pathway to clinical development.

The Integration of Drug Substance and Drug Product

This webinar highlights how a fully integrated program can speed up transition from candidate selection to proof of concept and shorten the pathway to clinical development.

DCAT Lunch Seminar: Integrated Drug Substance & Drug Product Strategies

Save your spot at our DCAT Week lunch seminar on March 23rd, entitled: Accelerating Development Through Integrated Drug Substance & Drug Product Strategies: Fully integrated programs to shorten the clinical pathway

Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.